Association between perceived school climate and employment anxiety among medical undergraduates: the mediating role of intentional self-regulation and the moderating role of perceived employability
Emotion regulation difficulties and experiential avoidance in adolescents with non-suicidal self-injury: a latent profile and moderation analysis
STAT+: Definium’s LSD therapy eased anxiety in second large trial
Definium Therapeutics said Monday that its LSD therapy helped patients with anxiety in a second late-stage trial, setting up the company to seek the first approval of a psychedelic drug for anxiety.
In the 12-week trial, patients taking a 100-microgram dose of the drug, called DT120, experienced a 9.8-point drop on a test called the Hamilton Anxiety Rating Scale, while those on placebo experienced a 4.7-point drop. The difference of 5.1 points is similar to what was seen in Definium’s first late-stage anxiety study and larger than what’s been observed with many other anxiety therapies, though it’s difficult to compare results across studies.
Definium is among the first wave of biotechs nearing regulatory approval for psychedelic therapies, a class of treatments that may be especially attractive to patients since they appear to exert rapid benefits. (In the latest trial, Definium said patients experienced changes as early as the second day after dosing.) In contrast, the effects of traditional options like antidepressants take weeks to kick in.
Screening and Monitoring of Mental Health in Educational Settings: Programme for Detection, Psychoeducation and Self-help
Interventions: Other: program for the detection, referral, and psychoeducation in adolescents
Sponsors: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Hospital Universitario Rey Juan Carlos; Hospital Universitario Infanta Elena; Universidad Carlos III de Madrid; Centro de Investigación Biomédica en Red de Salud Mental
Completed
Recovery-phase symptoms after COVID-19 infection and anxiety levels among college students
Renaclic for Chronic Kidney Disease Self-Management: Formative User-Centered Co-Design Study
Background: Chronic kidney disease (CKD) affects over 850 million individuals worldwide and requires sustained patient education, shared decision-making, and self-management support. Digital health platforms may facilitate these needs; however, many lack comprehensive, user-centered design and fail to address practical and psychosocial patient concerns. Objective: This study aimed to describe the formative co-design of Renaclic, a digital platform developed with patients and health care professionals (HCPs) to support CKD education and self-management in the French health care context. Methods: A three-stage user-centered design (UCD) study was conducted between April and August 2021. Stage 1 included benchmarking of 10 French-language CKD platforms and semistructured interviews with 8 stakeholders (3 HCPs: 1 nephrologist, 1 general practitioner, 1 nurse; 5 patients: 2 novice and 3 expert users). Stage 2 consisted of two virtual co-design focus groups incorporating card-sorting and interface design activities. Stage 3 translated identified needs into structured content categories and a low-fidelity prototype. Qualitative data were analyzed thematically. Results: Benchmarking revealed fragmented educational content, limited practical guidance on home dialysis logistics, insufficient coverage of lifestyle and psychosocial concerns, and minimal interactive features. Interviews identified five main themes: need for reliable centralized information, anxiety during care transitions, demand for practical lifestyle guidance, importance of reassuring language, and value of moderated peer exchange. More than 30 thematic content items were generated and organized through card-sorting into five consolidated content categories that structured the platform’s information architecture. Co-design sessions informed mobile accessibility, simplified navigation pathways, and integration of educational, symptom-tracking, and community-oriented functionalities. Conclusions: This formative study demonstrates how participatory UCD with diverse CKD stakeholders can generate a structured, context-sensitive digital platform framework. Renaclic provides a replicable model for early-stage co-design of digital health interventions in chronic disease management. Future research will evaluate usability, engagement, and implementation in real-world settings.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/ba7e69d2448a2fd5498156332504853e" />
Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health
Interventions: Behavioral: AIP-Informed Integrative Psychotherapy; Device: Transcutaneous Auricular Vagus Nerve Stimulation; Behavioral: Regulated Breathing and Autonomic Regulation; Device: Audiovisual Entrainment; Device: Vibroacoustic Stimulation; Behavioral: Breathwork-Based Auditory Driving Entropy Module (BADEM); Device: Transcranial Electrical Stimulation
Sponsors: Tactical Mind Research Coalition, Inc.
Active, not recruiting
Heart Rate Variability Biofeedback for Anxiety in Autistic Youth
Interventions: Device: Lief Smart Patch
Sponsors: Massachusetts General Hospital; Eagles Autism Foundation
Not yet recruiting
Facing Fears From Home: Development, Feasibility and Maximization of FobiApp
Interventions: Behavioral: FobiApp AR Exposure therapy, Self-administered augmented reality exposure for cockroach phobia; Behavioral: FobiApp AR Exposure therapy + ABM, Self- administered augmented reality exposure combined with attentional bias modification training for cockroach phobia.
Sponsors: Universitat Jaume I; Generalitat Valenciana
Not yet recruiting

